IL131730A - Screening methods to identify factors that selectively inhibit hepatitis C virus replication - Google Patents

Screening methods to identify factors that selectively inhibit hepatitis C virus replication

Info

Publication number
IL131730A
IL131730A IL13173098A IL13173098A IL131730A IL 131730 A IL131730 A IL 131730A IL 13173098 A IL13173098 A IL 13173098A IL 13173098 A IL13173098 A IL 13173098A IL 131730 A IL131730 A IL 131730A
Authority
IL
Israel
Prior art keywords
pkr
ns5a
protein
isdr
viral
Prior art date
Application number
IL13173098A
Other languages
English (en)
Hebrew (he)
Other versions
IL131730A0 (en
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL131730A0 publication Critical patent/IL131730A0/xx
Publication of IL131730A publication Critical patent/IL131730A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL13173098A 1997-03-05 1998-03-05 Screening methods to identify factors that selectively inhibit hepatitis C virus replication IL131730A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3859697P 1997-03-05 1997-03-05
PCT/US1998/004226 WO1998039487A1 (en) 1997-03-05 1998-03-05 Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication

Publications (2)

Publication Number Publication Date
IL131730A0 IL131730A0 (en) 2001-03-19
IL131730A true IL131730A (en) 2004-06-20

Family

ID=21900807

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13173098A IL131730A (en) 1997-03-05 1998-03-05 Screening methods to identify factors that selectively inhibit hepatitis C virus replication

Country Status (14)

Country Link
US (3) US6030785A (de)
EP (1) EP0975809A4 (de)
JP (1) JP2001514508A (de)
KR (1) KR20000075983A (de)
CN (1) CN1268980A (de)
AU (1) AU726374B2 (de)
CA (1) CA2283379A1 (de)
HU (1) HUP0001395A3 (de)
IL (1) IL131730A (de)
NO (1) NO994295L (de)
NZ (1) NZ337703A (de)
PL (1) PL335721A1 (de)
TR (1) TR199902561T2 (de)
WO (1) WO1998039487A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
CA2270898A1 (en) 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
NZ337703A (en) 1997-03-05 2001-05-25 Univ Washington A screening method to identify agents that selectively inhibit Hepatitis C virus replication in viruses that contain an ISDR region
DK1085904T3 (da) * 1998-06-12 2013-02-25 Sinai School Medicine Svækkede minusstreng-vira med ændret interferon-antagonist-aktivitet til anvendelse som vacciner og lægemidler
US20020004202A1 (en) * 2000-01-24 2002-01-10 Cornish Virginia W. In vivo screen using chemical inducers of dimerization
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US20020061579A1 (en) * 2000-08-09 2002-05-23 Farrand Stephen K. Counter selection strategy for Gram-negative bacteria
WO2002022880A1 (en) * 2000-09-13 2002-03-21 University Of Chicago Compositions and methods for the identification of viral inhibitors of host cell protein synthesis shut-off
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
US6699657B2 (en) * 2001-01-31 2004-03-02 Bristol-Myers Squibb Company In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses
AU2002259130A1 (en) * 2001-05-03 2002-11-18 Eli Lilly And Company Agents for treatment of hcv and methods of use
WO2003025209A1 (en) * 2001-09-21 2003-03-27 Ortho-Clinical Diagnostics, Inc. Use of hcv core antigen assay for screening of anti-viral compounds
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス(ケイマン)リミテツド 4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Hcv 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
SI3025726T1 (sl) 2002-01-18 2020-03-31 Biogen Ma Inc. Spojine polimera polialkilena in njihova uporaba
US7083918B2 (en) * 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
WO2003095972A2 (en) * 2002-05-09 2003-11-20 The Regents Of The University Of California Method of analyzing ataxia-telangiectasia protein
US6690975B2 (en) * 2002-05-17 2004-02-10 Bistner Co., Ltd. Methods for treating hepatitis C
EP1552021A4 (de) * 2002-06-11 2006-06-14 Idaho Res Foundation Mit interferon typ i induzierbare proteine zum nachweis einer virusinfektion
JP2005532071A (ja) * 2002-07-10 2005-10-27 ストラタジーン カリフォルニア 足場としてのヒト化レニラ・レニフォルミス緑色蛍光タンパク質
AU2003261434A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
AU2004258750A1 (en) * 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
ATE374838T1 (de) * 2004-04-29 2007-10-15 Hoffmann La Roche Nukleotidsequenzvariation im gen ns5a als marker
ES2694123T3 (es) 2004-06-01 2018-12-18 Icahn School Of Medicine At Mount Sinai Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
AU2005275181A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (de) * 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridine zur behandlung von hepatitis c
ES2349153T3 (es) * 2004-09-29 2010-12-28 The Administrators Of The Tulane Educational Fund Inhibidores del virus de la hepatitis c.
US7414031B2 (en) * 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
US8137676B2 (en) * 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
WO2006093987A1 (en) * 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside compounds for treating viral infections
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006138744A2 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
WO2007058384A1 (en) * 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
EA201100813A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
EP2007889A2 (de) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmazeutische zusammensetzungen mit anti-mirna-antisense-oligonukleotiden
WO2008002165A2 (en) * 2006-06-30 2008-01-03 Krzysztof Kucharczyk A method, assay and kit for prediction and treatment of a human subject infected with a virus
RU2009105837A (ru) * 2006-07-20 2010-08-27 СмитКлайн Бичем Копэрейшн (US) Полициклические противовирусные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусной инфекции с ее помощью и названные соединения для изготовления лекарственных средств
KR100783287B1 (ko) * 2006-08-09 2007-12-06 한국생명공학연구원 텔로미어 전사 비활성화에 관여하는 화합물의 동정을 위한균주의 제조
ES2603379T3 (es) * 2006-10-09 2017-02-27 Roche Innovation Center Copenhagen A/S Compuestos antagonistas de ARN para la modulación de PCSK9
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
US8470791B2 (en) * 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
US20110054011A1 (en) * 2007-08-30 2011-03-03 Mccullagh Keith RNA Antagonist Compounds for the Modulation of FABP4/AP2
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
US20090162858A1 (en) * 2007-09-18 2009-06-25 Cornish Virginia W Orthogonal chemical inducer of dimerization
CN101821391B (zh) * 2007-10-04 2016-04-27 桑塔里斯制药公司 微小聚体
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
CN101314614B (zh) * 2008-06-16 2011-03-23 南开大学 与pkr激酶结构域特异性结合的多肽及其应用
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (de) 2009-07-21 2012-05-30 Santaris Pharma A/S Auf pcsk9 gerichtete antisense-oligomere
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
CN103025728B (zh) 2010-07-22 2015-11-25 诺华股份有限公司 2,3,5-三取代的噻吩化合物及其用途
US9351989B2 (en) 2010-12-29 2016-05-31 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2013103829A1 (en) * 2012-01-05 2013-07-11 Viracine Therapeutics Corporation Compositions and methods for screening antiviral agents
MX391977B (es) 2013-06-27 2025-03-21 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
EP3261664A1 (de) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalenter schweineinfluenzavirusimpfstoff
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
EP3612190A4 (de) * 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated Regulierung der ran-translation durch pkr- und eif2a-p-wege
WO2019060918A1 (en) 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS
US12436154B2 (en) 2019-09-20 2025-10-07 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5738985A (en) * 1993-04-02 1998-04-14 Ribogene, Inc. Method for selective inactivation of viral replication
NZ337703A (en) 1997-03-05 2001-05-25 Univ Washington A screening method to identify agents that selectively inhibit Hepatitis C virus replication in viruses that contain an ISDR region

Also Published As

Publication number Publication date
NZ337703A (en) 2001-05-25
TR199902561T2 (xx) 2000-02-21
AU6684098A (en) 1998-09-22
WO1998039487A1 (en) 1998-09-11
CA2283379A1 (en) 1998-09-11
PL335721A1 (en) 2000-05-08
US6030785A (en) 2000-02-29
HUP0001395A1 (en) 2000-07-28
US20020155431A1 (en) 2002-10-24
EP0975809A1 (de) 2000-02-02
KR20000075983A (ko) 2000-12-26
AU726374B2 (en) 2000-11-02
NO994295D0 (no) 1999-09-03
US7148006B2 (en) 2006-12-12
CN1268980A (zh) 2000-10-04
EP0975809A4 (de) 2002-10-30
JP2001514508A (ja) 2001-09-11
US6326151B1 (en) 2001-12-04
HUP0001395A3 (en) 2001-09-28
IL131730A0 (en) 2001-03-19
NO994295L (no) 1999-11-02

Similar Documents

Publication Publication Date Title
US6030785A (en) Screening methods to identify agents that selectively inhibit hepatitis C virus replication
Gale Jr et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
JP4191797B2 (ja) 組み換えc型肝炎ウイルスrnaレプリカーゼ
Francois et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
Ishii et al. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding
Kato et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses
Podevin et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner
JP3280384B2 (ja) C型肝炎ウイルス(hcv)のns3プロテアーゼの蛋白分解活性のインビトロにおける再生方法
Reed et al. Molecular characterization of hepatitis C virus
WO1997012033A9 (en) Recombinant hepatitis c virus rna replicase
MXPA05004276A (es) Ns3 de proteasa de hcv resistente a inhibidor.
Noguchi et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells
Ahn et al. Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus
WO1995032291A2 (en) Hepatitis g virus and molecular cloning thereof
JP2015534821A (ja) Hcv遺伝子型6レプリコン
US20020081574A1 (en) Methods for identifying inhibitors of helicase C virus
Xiang et al. GB virus type C NS5A sequence polymorphisms: association with interferon susceptibility and inhibition of PKR-mediated eIF2α phosphorylation
US6639053B1 (en) HCV-derived RNA polymerase gene
US7504205B2 (en) Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
Yamada et al. Critical point mutations for hepatitis C virus NS3 proteinase
CZ314999A3 (cs) Způsoby pro vyhledávání nových antivirových činidel
US20040229213A1 (en) Exhaustive analysis of viral protein interactions by two-hybrid screens and selection of correctly folded viral interacting polypeptides
US20010055756A1 (en) Internal de novo initiation sites of the HCV NS5B polymerase and use thereof
HK1031899A (en) Novel screening methods to identify agents that selectively inhibit hepatitus c virus replication
WO2001022984A1 (en) Hcv e2 protein binding agents for treatment of hepatitis c virus infection

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
MM9K Patent not in force due to non-payment of renewal fees